STOCK TITAN

Odysight.ai nine-month revenue falls 64% in 2026

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Odysight.ai Inc. (ODYS) reported nine-month revenue of $926,000, versus $2.576 million a year earlier, and net loss of $13.719 million versus $12.756 million. The revenue comparison largely reflects $1.862 million recorded in the first quarter of 2025 for a medical customer, including $1.690 million from a nonrecurring contract-liability derecognition. Third-quarter revenue was $424,000 versus $149,000; the company linked growth to completed, new and continuing projects.

Nine-month operating cash use was $13.014 million, versus $9.821 million. At September 30, 2026, cash and cash equivalents plus restricted deposit totaled approximately $23.2 million; management expects existing cash to fund its plan for at least 12 months but expects to need more capital before profitability. The August 21, 2026 offering of 3,437,500 shares at $3.20 generated approximately $9.8 million net proceeds. Backlog and remaining performance obligations were each approximately $16.0 million; the company reported some security-related delays in customer orders and project deliveries.

On November 12, 2026, the board adopted bylaws ending stockholder action by written consent and revising director-removal rules. Director Inbal Kreiss adopted an August 31, 2026 Rule 10b5-1 arrangement for sales of up to 61,025 shares issuable upon option exercise.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • Moderate pointThird-quarter revenue rose 185% to $424,000 year over year.

Negative

  • Major pointNine-month net loss was $13.719 million, versus $12.756 million in 2025.
  • Moderate pointNine-month revenue fell 64% to $926,000 year over year.
  • Moderate pointNine-month operating cash use was $13.014 million, versus $9.821 million.

Filing Explained

The proposed 548,283-share increase remains subject to stockholder approval, so it expands potential award capacity rather than reporting an issuance.

The bylaws adopted on November 12, 2026 took effect immediately and change director-removal rules: stockholders may remove directors by a two-thirds vote, or a higher threshold if required by the articles, replacing the former cause requirement and 70% threshold.

The board also approved an increase of 548,283 shares to the 2024 plan pool, subject to stockholder approval; if approved, it would add capacity for future awards, not itself report an issuance.

Nine-month revenue $926,000 Nine months ended September 30, 2026; $2,576,000 in 2025, a reported 64% decrease.
Third-quarter revenue $424,000 Three months ended September 30, 2026; $149,000 in 2025, a reported 185% increase.
Nine-month net loss $13,719,000 Nine months ended September 30, 2026; $12,756,000 in 2025.
Cash used in operating activities $13,014,000 Nine months ended September 30, 2026; $9,821,000 in 2025.
Cash and cash equivalents plus restricted deposit Approximately $23.2 million As of September 30, 2026; approximately $26.0 million as of December 31, 2025.
Public offering net proceeds Approximately $9.8 million August 21, 2026 offering of 3,437,500 shares at $3.20 per share.
Backlog Approximately $16.0 million As of September 30, 2026; approximately $13.8 million as of December 31, 2025.
Remaining performance obligations Approximately $16.0 million As of September 30, 2026.
contract liability financial
"full derecognition of the contract liability"
A contract liability is a legally binding obligation a company has under a contract to deliver goods, services, or a refund in the future in exchange for money or another benefit already received. Investors care because these obligations represent future cash outflows or performance risks—like an IOU on a household chore list—that can reduce available cash, affect earnings reliability, and change how risky or valuable a company’s financial position looks.
Remaining Performance Obligations financial
"contracted revenue that has not yet been recognized"
Remaining performance obligations are the work a company still needs to complete for its customers, like finishing a service or delivering a product. It’s important because it shows how much future income the company has coming in from current agreements, giving a clearer picture of its ongoing business.
unbilled receivables financial
"revenue recognized for goods or services delivered, but not yet invoiced"
Amounts for goods or services a company has delivered or completed but has not yet invoiced the customer; think of it as work done where the bill hasn’t gone out. For investors, unbilled receivables signal revenue that is likely to become billed and collected in the near term, affecting future cash flow and earnings, but large or growing balances can also indicate billing delays, contract disputes, or collectability risks.
anti-dilutive financial
"excluded from the computation because their effect would have been anti-dilutive"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.
Rule 10b5-1 trading arrangement regulatory
"adopted a trading arrangement for the sale of shares"
Black-Scholes option-pricing model financial
"estimates the fair value of stock option awards"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was ODYS's third-quarter 2026 revenue?

Odysight.ai reported revenue of $424,000 for the three months ended September 30, 2026, compared with $149,000 in the same period of 2025. The company attributed the increase to completed ongoing projects, commencement of new projects and continued progress on existing projects.

Why did ODYS's revenue fall for the first nine months of 2026?

Revenue for the nine months ended September 30, 2026 was $926,000, versus $2.576 million in 2025. The company said the prior-year comparison included $1.862 million in first-quarter revenue from a Fortune 500 medical customer, including $1.690 million from full derecognition of a contract liability after it did not expect to receive a purchase order.

How many shares did ODYS director Inbal Kreiss's trading plan cover?

On August 31, 2026, Inbal Kreiss, a member of ODYS's board, adopted a Rule 10b5-1 arrangement for sales of common stock issuable upon exercise of options. It covers no more than 61,025 shares and expires on the earlier of November 30, 2027, and completion of all sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0001577445 0001577445 2026-01-01 2026-09-30 0001577445 2026-11-16 0001577445 2026-09-30 0001577445 2025-12-31 0001577445 us-gaap:RelatedPartyMember 2026-09-30 0001577445 us-gaap:RelatedPartyMember 2025-12-31 0001577445 us-gaap:NonrelatedPartyMember 2026-09-30 0001577445 us-gaap:NonrelatedPartyMember 2025-12-31 0001577445 2025-01-01 2025-09-30 0001577445 2026-07-01 2026-09-30 0001577445 2025-07-01 2025-09-30 0001577445 us-gaap:CommonStockMember 2025-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001577445 us-gaap:RetainedEarningsMember 2025-12-31 0001577445 us-gaap:CommonStockMember 2026-06-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001577445 us-gaap:RetainedEarningsMember 2026-06-30 0001577445 2026-06-30 0001577445 us-gaap:CommonStockMember 2024-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001577445 us-gaap:RetainedEarningsMember 2024-12-31 0001577445 2024-12-31 0001577445 us-gaap:CommonStockMember 2025-06-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001577445 us-gaap:RetainedEarningsMember 2025-06-30 0001577445 2025-06-30 0001577445 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001577445 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001577445 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001577445 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001577445 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001577445 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001577445 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001577445 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001577445 us-gaap:CommonStockMember 2026-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001577445 us-gaap:RetainedEarningsMember 2026-09-30 0001577445 us-gaap:CommonStockMember 2025-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001577445 us-gaap:RetainedEarningsMember 2025-09-30 0001577445 2025-09-30 0001577445 ODYS:LeaseAgreementMember 2023-06-25 2023-06-25 0001577445 ODYS:FirstYearMember 2026-03-01 2026-03-31 0001577445 ODYS:SecondYearMember 2026-03-01 2026-03-31 0001577445 ODYS:LeaseAgreementMember 2023-05-01 2023-05-31 0001577445 2023-05-01 2023-05-31 0001577445 us-gaap:VehiclesMember 2026-09-30 0001577445 ODYS:OfficeLeaseMember 2026-09-30 0001577445 us-gaap:InvestorMember 2021-03-28 2021-03-29 0001577445 us-gaap:InvestorMember 2021-03-29 0001577445 ODYS:StockPurchaseAgreementsMember 2023-03-15 2023-03-16 0001577445 ODYS:StockPurchaseAgreementsMember 2023-03-16 0001577445 ODYS:StockPurchaseAgreementsMember 2026-01-01 2026-03-31 0001577445 ODYS:UnderwritingAgreementMember ODYS:UnderwritersMember 2025-02-12 2025-02-12 0001577445 ODYS:UnderwritingAgreementMember ODYS:UnderwritersMember 2025-02-12 0001577445 us-gaap:OverAllotmentOptionMember 2025-02-14 2025-02-14 0001577445 us-gaap:OverAllotmentOptionMember 2025-02-14 0001577445 us-gaap:CommonStockMember 2025-02-14 2025-02-14 0001577445 ODYS:UnderwritingAgreementMember ODYS:UnderwritersMember 2026-08-21 2026-08-21 0001577445 ODYS:UnderwritingAgreementMember ODYS:UnderwritersMember 2026-08-21 0001577445 ODYS:UnderwritersMember 2026-08-21 2026-08-21 0001577445 us-gaap:CommonStockMember 2026-08-21 2026-08-21 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember 2020-02-01 2020-02-29 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:BoardOfDirectorsMember 2020-03-14 2020-03-15 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember 2020-06-22 2020-06-22 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:BoardOfDirectorsMember 2021-04-01 2021-06-30 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:BoardOfDirectorsMember 2023-01-01 2023-03-31 0001577445 ODYS:TwoThousandAndTwentyFourShareIncentivePlanMember ODYS:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember 2020-02-01 2020-02-29 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:BoardOfDirectorsMember 2024-07-01 2024-07-31 0001577445 ODYS:TwoThousandAndTwentyFourShareIncentivePlanMember ODYS:BoardOfDirectorsMember 2025-12-01 2025-12-31 0001577445 ODYS:TwoThousandAndTwentyFourShareIncentivePlanMember ODYS:BoardOfDirectorsMember 2026-10-01 2026-10-31 0001577445 us-gaap:StockOptionMember 2026-01-01 2026-09-30 0001577445 srt:MinimumMember 2026-09-30 0001577445 srt:MaximumMember 2026-09-30 0001577445 srt:MinimumMember 2026-01-01 2026-09-30 0001577445 srt:MaximumMember 2026-01-01 2026-09-30 0001577445 ODYS:DesignatedOptionsMember 2026-02-19 2026-02-19 0001577445 ODYS:DesignatedOptionsMember 2026-02-19 0001577445 srt:MinimumMember ODYS:DesignatedOptionsMember 2026-02-19 2026-02-19 0001577445 srt:MaximumMember ODYS:DesignatedOptionsMember 2026-02-19 2026-02-19 0001577445 us-gaap:EmployeeStockOptionMember 2025-12-31 0001577445 us-gaap:EmployeeStockOptionMember 2024-12-31 0001577445 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001577445 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001577445 us-gaap:EmployeeStockOptionMember 2026-09-30 0001577445 us-gaap:EmployeeStockOptionMember 2025-09-30 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2025-09-30 0001577445 us-gaap:CostOfRevenue 2026-01-01 2026-09-30 0001577445 us-gaap:CostOfRevenue 2025-01-01 2025-09-30 0001577445 us-gaap:CostOfRevenue 2026-07-01 2026-09-30 0001577445 us-gaap:CostOfRevenue 2025-07-01 2025-09-30 0001577445 us-gaap:ResearchAndDevelopmentExpense 2026-01-01 2026-09-30 0001577445 us-gaap:ResearchAndDevelopmentExpense 2025-01-01 2025-09-30 0001577445 us-gaap:ResearchAndDevelopmentExpense 2026-07-01 2026-09-30 0001577445 us-gaap:ResearchAndDevelopmentExpense 2025-07-01 2025-09-30 0001577445 us-gaap:SellingAndMarketingExpense 2026-01-01 2026-09-30 0001577445 us-gaap:SellingAndMarketingExpense 2025-01-01 2025-09-30 0001577445 us-gaap:SellingAndMarketingExpense 2026-07-01 2026-09-30 0001577445 us-gaap:SellingAndMarketingExpense 2025-07-01 2025-09-30 0001577445 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001577445 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001577445 us-gaap:GeneralAndAdministrativeExpense 2026-07-01 2026-09-30 0001577445 us-gaap:GeneralAndAdministrativeExpense 2025-07-01 2025-09-30 0001577445 ODYS:FortuneFiveHundredMedicalCompanyCustomerMember 2025-03-31 0001577445 ODYS:CustomizationAndDevelopmentServicesMember 2026-01-01 2026-09-30 0001577445 2025-01-01 2025-12-31 0001577445 ODYS:OptionsMember 2026-01-01 2026-09-30 0001577445 ODYS:OptionsMember 2025-01-01 2025-12-31 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-12-31 0001577445 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001577445 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001577445 us-gaap:CorporateMember 2026-01-01 2026-09-30 0001577445 us-gaap:CorporateMember 2025-01-01 2025-09-30 0001577445 us-gaap:CorporateMember 2026-07-01 2026-09-30 0001577445 us-gaap:CorporateMember 2025-07-01 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ODYS:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission File No. 001-42497

 

ODYSIGHT.AI INC.
(Exact name of registrant as specified in its charter)

 

Nevada   47-4257143
(State or other jurisdiction   (I.R.S. Employer
of incorporation or organization)   Identification No.)

 

12 Abba Hillel Silver RD, Sasson Hugi Tower    
Ramat Gan, Israel   5250606
(Address of Principal Executive Offices)   (Zip Code)

 

+972 73 370-4690
(Registrant’s telephone number, including area code)

 

 
(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.001 per share   ODYS   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

☐ Large accelerated filer ☐ Accelerated filer
☒ Non-accelerated filer ☒ Smaller reporting company
    ☐ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 16, 2026, the registrant had 20,244,405 shares of common stock, par value $0.001 per share, of the registrant issued and outstanding.

 

As used in this Quarterly Report and unless otherwise indicated, the terms “Odysight.ai,” “we,” “us,” “our,” or “our Company” refer to Odysight.ai. Unless otherwise specified, all dollar amounts are expressed in United States dollars.

 

 

 

 
 

 

ODYSIGHT.AI INC.

 

QUARTERLY REPORT ON FORM 10-Q

 

TABLE OF CONTENTS

 

    Page
     
Special Note Regarding Forward-Looking Statements 3
     
PART I-FINANCIAL INFORMATION  
     
Item 1. Consolidated Financial Statements (unaudited) 4
     
  Consolidated Balance Sheets 5
     
  Consolidated Statements of Operations and Comprehensive Loss 7
     
  Statements of Stockholders’ Equity 8
     
  Consolidated Statements of Cash Flows 9
     
  Notes to Consolidated Financial Statements 11
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 27
     
Item 4. Controls and Procedures 27
     
PART II-OTHER INFORMATION  
     
Item 1. Legal Proceedings 28
     
Item 1A. Risk Factors 28
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28
     
Item 3. Defaults Upon Senior Securities 28
     
Item 4. Mine Safety Disclosures 28
     
Item 5. Other Information 28
     
Item 6. Exhibits 29
     
SIGNATURES 30

 

-2-
 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

 

  ● our ability to scale up our operations, including market acceptance and large-scale adoption of our vision-based sensor products;
     
  ● the amount and timing of future sales and our long and unpredictable sales cycles;
     
  ● our ability to maintain product quality and performance at an acceptable cost and meet technical and quality specifications;
     
  ● our ability to accurately estimate the future supply and demand for our solutions and changes to various factors in our supply chain;
     
  ● the market for adoption of vision-based sensor technologies;
     
  ● compliance with existing laws and regulations and regulatory developments in the United States, Israel, and other jurisdictions, including trade control laws, export authorizations and safety regulations;
     
  ● our plans and ability to obtain, maintain, and protect intellectual property rights, including extensions of patent terms, and our ability to avoid infringing the intellectual property rights of others;
     
  ● the need to hire additional personnel and our ability to attract and retain such personnel, including key members of our senior management;
     
  ● our estimates regarding expenses, backlog, future revenue, capital requirements and need for additional financing;
     
  ● our dependence on third parties, including suppliers and strategic partners;
     
  ● our dependence on a limited number of customers for a substantial portion of our revenues and the impact if order volumes from existing or anticipated customers do not meet expectations;
     
  ● our financial performance and history of operating losses;
     
  ● the growth of regulatory requirements and incentives;
     
  ● the incorporation of artificial intelligence, or AI, and machine learning, or ML, into our products;
     
  ● risks related to product liability claims or product recalls;
     
  ● cybersecurity risks and potential data security breaches;
     
  ● the overall global economic environment and trade tensions, including the adoption or expansion of economic sanctions, tariffs or trade restrictions;
     
  ● challenges and risks related to sales to government entities and highly regulated organizations;
     
  ● the impact of competition and new technologies;
     
  ● limitations and exclusivity provisions in our customer agreements and restrictions on the use of intellectual property;
     
  ● our ability to ensure that our solutions interoperate with a variety of hardware and software platforms;
     
  ● our plans to continue to invest in research and develop technology for new products;
     
  ● our plans to potentially acquire complementary businesses;
     
  ● the impact of future pandemics on our business and on the business of our customers;
     
  ● fluctuations in foreign currency exchange rates;
     
  ● security, political and economic instability in the Middle East that could harm our business, including due to the security situation in Israel and military conflicts with Iran and terrorist organizations, political uncertainty in Israel, including with respect to the formation of a government and the approval of a state budget, and potential reductions in U.S. military aid to Israel;
     
  ● the increased expenses and requirements associated with being a listed public company on the Nasdaq Capital Market, or Nasdaq; and
     
  ● risks associated with our dual listing on the Tel Aviv Stock Exchange, or the TASE, including price volatility, liquidity, and regulatory requirements.

 

Forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions, are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, actual results may differ materially from those anticipated or implied in the forward-looking statements due to factors described in “Risk Factors” in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2025 (filed on March 19, 2026). In addition, management’s assumptions about future events may prove to be inaccurate. All readers are cautioned that the forward-looking statements contained in this Quarterly Report on Form 10-Q are not guarantees of future performance, and we cannot assure any reader that such statements will be realized or that the forward-looking events and circumstances will occur. Readers are urged to consider these factors carefully in evaluating the forward-looking statements. You should read our Annual Report on Form 10-K for the year ended December 31, 2025, and the documents that we reference in and have filed as exhibits thereto, completely and with the understanding that our actual future results may be materially different from what we expect.

 

Forward-looking statements included in this Quarterly Report on Form 10-Q speak only as of the date of this Quarterly Report on Form 10-Q. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the Securities and Exchange Commission, or the SEC, after the date of this Quarterly Report on Form 10-Q. We qualify all of our forward-looking statements by these cautionary statements.

 

-3-
 

 

Item 1. Financial Statements

 

ODYSIGHT.AI INC.

 

INTERIM FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2026

 

CONSOLIDATED ODYSIGHT.AI INC.

 

  Page
Interim Condensed Consolidated Financial Statements - in US Dollars (USD) in thousands  
Interim Condensed Consolidated Balance Sheets (unaudited) 5
Interim Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) 7
Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited) 8
Interim Condensed Consolidated Statements of Cash Flows (unaudited) 9
Notes to the Interim Condensed Consolidated Financial Statements 11

 

-4-
 

 

ODYSIGHT.AI INC.

 

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

 

   September 30,   December 31, 
   2026   2025 
   Unaudited     
   USD in thousands 
Assets          
           
CURRENT ASSETS:          
Cash and cash equivalents   22,815    25,677 
Restricted cash   -    333 
Restricted deposit   337    - 
Accounts receivable   470    278 
Unbilled receivables   757    615 
Inventory   472    50 
Other current assets   1,008    549 
Total current assets   25,859    27,502 
           
NON-CURRENT ASSETS:          
Property and equipment, net   189    346 
Operating lease right-of-use assets   685    739 
Severance pay asset   309    296 
Other non-current assets   96    96 
Total non-current assets   1,279    1,477 
           
TOTAL ASSETS   27,138    28,979 

 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

 

-5-
 

 

ODYSIGHT.AI INC.

 

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)

 

   September 30,   December 31, 
   2026   2025 
   Unaudited     
   USD in thousands 
Liabilities and shareholders’ equity          
           
CURRENT LIABILITIES:          
Accounts payable   556    480 
Advances from customers   95    165 
Operating lease liabilities - short term   484    511 
Accrued compensation expenses   1,474    1,400 
Related parties   107    115 
Other current liabilities   460    327 
Total current liabilities   3,176    2,998 
           
NON-CURRENT LIABILITIES:          
Operating lease liabilities - long term   189    259 
Liability for severance pay   309    296 
Total non-current liabilities   498    555 
           
TOTAL LIABILITIES   3,674    3,553 
           
SHAREHOLDERS’ EQUITY:          
Common stock, $0.001 par value; 300,000,000 shares authorized as of September 30, 2026 and December 31, 2025, 20,244,405 and 16,357,327 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   20    17 
Additional paid-in capital   100,172    88,418 
Accumulated deficit   (76,728)   (63,009)
TOTAL SHAREHOLDERS’ EQUITY   23,464    25,426 
           
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY   27,138    28,979 

 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

 

-6-
 

 

ODYSIGHT.AI INC.

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

   2026   2025   2026   2025 
  

Nine months ended

September 30,

  

Three months ended

September 30,

 
   2026   2025   2026   2025 
   Unaudited 
   USD in thousands 
     
REVENUES   926    2,576    424    149 
COST OF REVENUES   555    1,882    233    126 
GROSS PROFIT   371    694    191    23 
RESEARCH AND DEVELOPMENT EXPENSES   6,979    7,322    2,182    2,479 
SALES AND MARKETING EXPENSES   2,752    1,604    869    580 
GENERAL AND ADMINISTRATIVE EXPENSES   4,855    5,473    1,486    1,671 
OPERATING LOSS   (14,215)   (13,705)   (4,346)   (4,707)
FINANCING INCOME, NET   496    949    132    291 
NET LOSS AND COMPREHENSIVE LOSS   (13,719)   (12,756)   (4,214)   (4,416)
Net loss per common share (basic and diluted, USD)   (0.80)   (0.81)   (0.23)   (0.27)
Weighted average common shares (basic and diluted, in thousands)   17,180    15,747    18,339    16,331 

 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

 

-7-
 

 

ODYSIGHT.AI INC.

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

 

Nine Months Ended September 30, 2026 (Unaudited)

 

   Number   Amount   capital   deficit   equity 
   Common Stock  

Additional

paid-in

   Accumulated  

Total

Shareholders’

 
   Number   Amount   capital   deficit   equity 
   In thousands   USD in thousands 
Balance at January 1, 2026   16,358   $17   $88,418    (63,009)  $     25,426 
Issuance of shares, net of issuance cost   3,438    3    9,819    -    9,822 
Stock based compensation   -    -    1,802    -    1,802 
Issuance of shares upon RSU vesting   4    -*    -(*)    -    - 
Options exercise   37    -*    133    -    133 
Warrants exercise   407    -*    -(*)    -    - 
Net loss   -    -    -    (13,719)   (13,719)
Balance at September 30, 2026   20,244   $20   $100,172   $(76,728)  $23,464 

 

Three Months Ended September 30, 2026 (Unaudited)

 

   Common Stock  

Additional

paid-in

   Accumulated  

Total

Shareholders’

 
   Number   Amount   capital   Deficit   equity 
   In thousands   USD in thousands 
Balance as of July 1, 2026   16,806   $17   $89,889   $(72,514)  $17,392 
Issuance of shares, net of issuance cost   3,438    3    9,819    -    9,822 
Stock based compensation   -    -    464    -    464 
Net loss   -    -    -    (4,214)   (4,214)
Balance as of September 30, 2026   20,244   $20   $100,172   $(76,728)  $23,464 

 

Nine Months Ended September 30, 2025 (Unaudited)

 

   Common Stock  

Additional

paid-in

   Accumulated  

Total

Shareholders’

 
   Number   Amount   Capital   Deficit   Equity 
   In thousands   USD in thousands 
Balance at January 1, 2025   12,613   $13   $64,205    (45,974)  $  18,244 
Stock based compensation   -    -    2,565    -    2,565 
Issuance of shares upon RSU vesting   9    -*    -(*)    -    - 
Issuance of shares, net of issuance cost   3,653    4    20,863    -    20,867 
Options exercise   60    -*    194    -    194 
Net loss   -    -    -    (12,756)   (12,756)
Balance at September 30, 2025   16,335   $17   $87,827   $(58,730)  $29,114 

 

Three Months Ended September 30, 2025 (Unaudited)

 

   Common Stock  

Additional

paid-in

   Accumulated  

Total

Shareholders’

 
   Number   Amount   capital   Deficit   Equity 
   In thousands   USD in thousands     
Balance as of July 1, 2025   16,327   $17   $86,901   $(54,314)  $32,604 
Stock based compensation   -    -    914    -    914 
Issuance of shares upon RSU vesting   4    -*    -(*)    -    - 
Options exercise   4    -    12    -    12 
Net loss   -    -    -    (4,416)   (4,416)
Balance as of September 30, 2025   16,335   $17   $87,827   $(58,730)  $29,114 

 

* Represents an amount less than $1 thousand

 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

 

-8-
 

 

ODYSIGHT.AI INC.

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   2026   2025   2026   2025 
  

Nine months ended

September 30,

  

Three months ended

September 30,

 
   2026   2025   2026   2025 
   Unaudited 
   USD in thousands 
                 
CASH FLOWS FROM OPERATING ACTIVITIES:                    
Net loss   (13,719)   (12,756)   (4,214)   (4,416)
Adjustments to reconcile net loss to net cash used in operations:                    
Depreciation   82    88    26    30 
Stock based compensation   1,802    2,565    464    914 
Loss (Profit) from exchange differences   (29)   (18)   16    24 
Loss from sales of property and equipment   97    -    43    - 
Interest in respect of deposits   (7)   12    (4)   - 
                     
Changes in operating assets and liability items:                    
Decrease (increase) in accounts receivable   (224)   1,186    183    163 
Decrease (increase) in inventory   (422)   203    (228)   - 
Decrease in operating lease liability   (411)   (374)   (141)   (132)
Increase in unbilled receivables   (142)   -    (75)   - 
Decrease in right-of-use asset   352    366    121    127 
Increase in current and non-current other assets   (454)   (557)   (254)   (30)
Decrease in account payables   (24)   (65)   (11)    (191)
Increase (decrease) in related parties   (8)   110    (6)   75 
Decrease in contract fulfillment assets   -    1,017    -    - 
Increase (decrease) in current and non-current contract liabilities and advances from customers   (70)   (1,835)   (247)   (39)
Increase (decrease) in accrued compensation expenses   23    44    (74)   (78)
Increase in current and non-current other liabilities   140    193    100    135 
Net cash flows used in operating activities   (13,014)   (9,821)   (4,301)   (3,418)
                     
CASH FLOWS FROM INVESTING ACTIVITIES:                    
                     
Purchase of property and equipment   (52)   (41)   (18)   (11)
Proceeds from sales of property and equipment   30    -    9    - 
Withdrawal of (investment in) short term deposits   (330)   310    -    - 
Net cash flows provided by (used in) investing activities   (352)   269    (9)   (11)
                     
CASH FLOWS FROM FINANCING ACTIVITIES:                    
Proceeds from issuance of shares, net of issuance cost (issuance cost)   9,943    20,867    9,943    (7)
Proceeds from options exercise   133    190    -    8 
Net cash flows provided by financing activities   10,076    21,057    9,943    1 
                     
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH   (3,290)   11,505    5,633    (3,428)
BALANCE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD   26,010    18,164    17,221    33,238 
EFFECT FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH   95    144    (39)   3 
BALANCE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT THE END OF THE PERIOD   22,815    29,813    22,815    29,813 
                     
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:                    
Cash and cash equivalents   22,815    29,482    22,815    29,482 
Restricted cash   -    331    -    331 
Total cash, cash equivalents and restricted cash   22,815    29,813    22,815    29,813 

 

-9-
 

 

Non-cash activities -

 

  

Nine months ended

September 30,

  

Three months ended

September 30,

 
   2026   2025   2026   2025 
   Unaudited 
   USD in thousands 
SUPPLEMENTAL INFORMATION FOR CASH FLOW:                
Right-of-use assets obtained in exchange for operating lease liabilities   374    122    -   44 
Termination of right-of-use assets in exchange for cancellation of operating lease obligations   (76)   (36)   -    (3)
Issuance cost   121    -    

121

    - 

 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

 

-10-
 

 

ODYSIGHT.AI INC.

 

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – GENERAL:

 

  a. Odysight.ai Inc. (the “Company”) was incorporated under the laws of the State of Nevada on March 22, 2013.
     
    The Company’s wholly owned subsidiary, Odysight.ai Ltd. (“Odysight.ai”), was incorporated in the State of Israel on January 3, 2019, and was merged into the Company on December 31, 2019 in a share exchange transaction, following which the surviving operations of the merged entity were the operations of Odysight.ai.
     
    On February 28, 2024, D. View Ltd., a wholly owned subsidiary of the Company, was incorporated in the State of Israel to act as a representative for the defense market.
     
   

On January 9, 2025, Odysight.ai Eu S.r.l., a wholly owned subsidiary of the Company, was incorporated under the laws of Italy.

 

References to the Company include the subsidiaries unless the context indicates otherwise.

     
    The Company, through its subsidiaries, provides vision-based solutions for the Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) markets. The Company’s visual sensor-based solutions, embedded software and AI algorithms are deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases and allow maintenance and operations teams visibility into areas which are inaccessible under normal operation, or where the operating ambience is not suitable for continuous real-time monitoring. By combining advanced visual sensing, real-time analytics, and AI-driven insights, the Company helps organizations improve safety, efficiency, and operational intelligence.
     
    On February 11, 2025, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “ODYS”. Prior to such date, the Company was quoted on the OTCQB under the same symbol. On April 9, 2026, the Company’s common stock began trading on the Tel Aviv Stock Exchange under the symbol “ODYS”.

 

  b. Since incorporation of Odysight.ai and through September 30, 2026, the Company accumulated a deficit of approximately $76.7 million and its activities have been funded mainly by its stockholders. The Company’s management believes the Company’s cash and cash equivalents will allow the Company to fund its operating plan through at least the next 12 months from the filing date of these interim condensed consolidated financial statements. However, the Company expects to continue to incur significant operational expenses related to its ongoing activities, requiring the Company to obtain additional funding in order to continue its future operations until becoming profitable.
     
  c.

On February 28, 2026, the United States and Israel attacked Iran, which responded with missile and drone attacks on Israel, U.S. forces and other targets in the region, causing civilian casualties and property damage in Israel. In March 2026, Hezbollah joined the conflict, leading to Israeli strikes and a ground incursion in Lebanon. Ceasefire arrangements reached between April and June 2026, including a June 2026 U.S.-Iran memorandum of understanding, have been repeatedly violated, and the memorandum collapsed in July 2026 amid renewed hostilities in the Strait of Hormuz, which remains largely closed to commercial shipping. The situation remains volatile and future developments are difficult to predict.

 

As a result of the above-described events, the Company has experienced some delays in customer orders and in deliveries of existing projects.

 

In the Company’s assessment, should the security situation continue for an extended period and/or escalate, its consequences may have a material adverse effect on the Israeli economy, including on the Company. Given that this is a dynamic event characterized by significant uncertainty, the extent of the impact of the security situation on the Company’s future operations is currently unknown.

 

-11-
 

 

ODYSIGHT.AI INC.

 

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

a. Unaudited Interim Financial Statements

 

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

 

b. Principles of Consolidation

 

The accompanying interim condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

 

c. Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment and stock-based compensation, as well as estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.

 

-12-
 

 

ODYSIGHT.AI INC.

 

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued):

 

d. Significant Accounting Policies

 

The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.

 

e. Recent Accounting Pronouncements

 

Recent accounting pronouncements are identical to those presented in the latest annual financial statements, except for the following:

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. ASU 2025-11 clarifies and improves existing interim reporting guidance by consolidating disclosure requirements within Topic 270 and introducing a disclosure principle requiring entities to disclose events and changes occurring after the most recent annual reporting period that are expected to have a material effect on the entity’s financial condition or results of operations. The ASU does not introduce significant changes to recognition or measurement guidance. The amendments in ASU 2025-11 are effective for interim reporting periods within fiscal years beginning after December 15, 2027, with early adoption permitted. ASU 2025-11 allows for either a prospective or retrospective approach on adoption. The Company is currently evaluating the impact of ASU 2025-11 on its consolidated financial statements and related disclosures.

 

NOTE 3 – LEASES:

 

  a. Omer office space

 

In December 2020, Odysight.ai entered into a lease agreement for office space in Omer, Israel (the “Original Space”), with the 36-month term for such agreement beginning on January 1, 2021. In March 2021, Odysight.ai entered into a lease agreement for additional office space in Omer, Israel (the “Additional Space”), with the term for such agreement ending on December 31, 2023.

 

On June 25, 2023, Odysight.ai entered into an amendment to these agreements pursuant to which the lease for the Additional Space was shortened and ended on June 30, 2023, and the lease for the Original Space was extended for an additional five years until December 31, 2028. It was also agreed that Odysight.ai has an option to terminate the agreement for the Original Space with six months’ notice during the first three years.

 

Monthly lease payments under the agreement for the Original Space are approximately $7 thousand.

 

In December 2025, the Company provided six months’ notice indicating its intention to terminate the lease agreement as of May 2026. In March 2026, the Company signed a two-year lease agreement for alternative office space in Omer, with the lease commencing on June 28, 2026. At the end of the term, the Company has an option to extend the lease for an additional two years, which the Company has not factored into its lease liability calculation. Monthly lease payments under the agreement are approximately $5 thousand in the first year and approximately $6 thousand in the second year.

 

  b. Ramat Gan office space

 

In May 2023, Odysight.ai entered into a lease agreement for office space in Ramat Gan, Israel. The agreement is for 48 months beginning on July 1, 2023, and the Company has an option to extend the lease period for an additional two years. The Company does not currently expect to extend the lease period. Monthly lease payments under the agreement are approximately $25 thousand.

 

Odysight.ai subleases part of the office space in Ramat Gan to a third party for approximately $8 thousand per month.

 

c. The Company leases vehicles for use by certain of its employees in Israel. The lease terms are typically for three-year periods.

 

Supplemental cash flow information related to operating leases was as follows:

 

   2026   2025   2026   2025 
  

Nine months ended

September 30,

  

Three months ended

September 30,

 
   2026   2025   2026   2025 
   Unaudited 
   USD in thousands 
                     
Cash paid for amounts included in the measurement of lease liabilities   463    451    159    155 

 

As of September 30, 2026, the Company’s operating leases had a weighted average remaining lease term of 0.75 years and a weighted average discount rate of 6% for vehicles and 12.8% for offices.

 

The maturities of lease liabilities under operating leases as of September 30, 2026, are as follows:

 

   Operating leases 
   USD in thousands 
Remainder of 2026   151 
2027   406 
2028   152 
2029   2 
Total future lease payments   711 
Less imputed interest   (38)
Total lease liability balance   673 

 

-13-
 

 

ODYSIGHT.AI INC.

 

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 4 – OTHER CURRENT LIABILITIES:

 

Other current liabilities consisted of the following:

 

  

September 30,

2026

  

December 31,

2025

 
   USD in thousands 
Government authorities   -    90 
Accrued expenses   343    209 
Other payables   117    28 
Total other current liabilities   460    327 

 

NOTE 5 – EQUITY:

 

  a. Private and Public Placements
     
  1.

On March 29, 2021, the Company issued to certain investors, including Moshe (Mori) Arkin, a major stockholder and director of the Company, an aggregate of 2,469,156 units in exchange for an aggregate purchase price of $20 million. Each such unit consisted of (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of the Company’s common stock with an exercise price of $10.35 per share. Each such warrant was exercisable until March 31, 2026 and subject to customary adjustments. Pursuant to the terms of the foregoing warrants, following April 1, 2024, if the closing price of the Company’s common stock equaled or exceeded 135% of the aforementioned exercise price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the warrants) for any thirty (30) consecutive trading days, the Company could force the exercise of the warrants, in whole or in part, by delivering to these investors a notice of forced exercise.

 

On March 31, 2026 all warrants expired.

     
  2.

On March 16, 2023, the Company entered into stock purchase agreements for a private placement with (i) Moshe (Mori) Arkin and (ii) The Phoenix Insurance Company Ltd. (“Phoenix Insurance”) and Shotfut Menayot Israel – Phoenix Amitim (“Phoenix Amitim”), in connection with the sale and issuance of an aggregate of 3,294,117 units, at a purchase price of $4.25 per unit, and for an aggregate purchase price of $14 million. Each unit consisted of: (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of the Company’s common stock. The warrants are immediately exercisable, expire three years from the date of issuance and are subject to customary adjustments.

 

During March 2026, all warrants were exercised on a cashless basis, and 407,497 shares were issued accordingly.

     
  3.

On February 12, 2025, the Company completed a U.S. underwritten public offering of 3,307,692 shares of the Company’s common stock at a price of $6.50 per share. The Company also granted the underwriters a 30-day over-allotment option to purchase up to an additional 496,153 shares at a purchase price of $6.50 per share. On February 14, 2025, the Company sold an additional 345,432 shares of common stock as a result of a partial exercise of the over-allotment option at the public offering price of $6.50 per share. Following the exercise of the over-allotment option, the Company sold a total of 3,653,124 shares of common stock, generating gross proceeds of approximately $23.7 million, prior to the deduction of underwriting discounts, commissions and estimated offering expenses. After deducting issuance costs, the Company received net proceeds of approximately $20.9 million.

 

  4.

On August 21, 2026, the Company completed an underwritten public offering of 3,437,500 shares of the Company’s common stock at a price of $3.20 per share. The Company also granted the underwriters a 30-day over-allotment option to purchase up to an additional 515,625 shares at a purchase price of $3.20 per share. The option expired without being exercised. The gross proceeds of the offering were approximately $11.0 million, prior to the deduction of underwriting discounts, commissions and offering expenses. After deducting issuance costs, the Company received net proceeds of approximately $9.8 million.

 

-14-
 

 

ODYSIGHT.AI INC.

 

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 5 – EQUITY (continued):

 

b. Stock-based compensation for employees, directors and service providers:

 

In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “2020 Plan”).

 

The 2020 Plan initially included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the 2020 Plan by an additional 64,099 shares of common stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the 2020 Plan by an additional 401,950 shares of common stock. During the second quarter of 2021, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the 2020 Plan by an additional 777,778 shares of common stock. During the first quarter of 2023, the Company’s Board of Directors approved an increase to the option pool pursuant to the 2020 Plan by an additional 1,000,000 shares of common stock.

 

In June 2024, the Company’s Board of Directors approved the 2024 Share Incentive Plan (the “2024 Plan”). With adoption of the 2024 Plan, the Company ceased making new awards under the 2020 Plan.

 

The 2024 Plan initially included a pool of 234,484 shares of common stock, representing the number of shares remaining available for grant under the 2020 Plan. These shares are available for future grant to Company employees, consultants, directors and other service providers. Shares that were subject to awards granted under either the 2020 Plan or the 2024 Plan that have expired, been cancelled or become unexercisable for any reason without having been exercised in full shall become available for future grant under the 2024 Plan.

 

In July 2024, the Company’s Board of Directors approved an increase to the 2024 Plan’s option pool by an additional 850,000 shares of common stock. Also in July 2024, the Company’s stockholders approved the 2024 Plan. In December 2025, the Company’s stockholders approved an increase to the 2024 Plan’s option pool by an additional 777,000 shares of common stock. In October 2026, the Company’s Board of Directors approved an increase to the 2024 Plan’s option pool by an additional 548,283 shares of common stock, which increase is subject to the approval of the Company’s stockholders.

 

The 2020 Plan and 2024 Plan each provide for the grant of stock options (including incentive stock options and nonqualified stock options), shares of common stock, restricted shares, restricted share units, and other share-based awards.

 

Stock option activity

 

The following table summarizes stock option activity for the nine months ended September 30, 2026 and September 30, 2025:

 

  

For the nine months ended

September 30,

 
   2026   2025 
   Amount of
options
   Weighted average
exercise price
($)
   Amount of
options
   Weighted average
exercise price
($)
 
Outstanding at beginning of period   3,340,514    3.95    3,227,234    3.78 
Granted   515,000    4.97    331,000    5.37 
Exercised   (37,914)   3.49    (61,065)   3.29 
Forfeited   (187,080)   4.09    (41,779)   4.14 
Outstanding at end of period   3,630,520    4.09    3,455,390    3.94 
                     
Vested at end of period   2,895,827    3.79    2,381,217    3.64 

 

The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option-pricing model. The weighted-average grant date fair value per option granted during the nine months ended September 30, 2026, was $3.85. The fair value of each award is estimated using the Black-Scholes option-pricing model based on the following assumptions: underlying value of shares of $4.64-$5.14, exercise price of $4.70-$5.14, expected volatility of 80.21%-89.28%, term of the options of 4.375-10 years and risk-free interest rate of 3.74%-4.67%.

 

On February 19, 2026, the Company’s Board of Directors approved a three-year extension of the term of 407,034 options that were originally set to expire in 2027 (the “Designated Options”). As a result of this extension, the Company estimated the fair value of the Designated Options both before and after the modification and recognized approximately $400 thousand in stock-based payment expenses. The fair value of the Designated Options was estimated using the Black-Scholes option-pricing model, based on the following assumptions: underlying value of shares of $5.14, exercise price of $2.61, expected volatility of 84.89%-90.02%, term of the options of 0.98-4.34 years and risk-free interest rate of 3.49%-3.575%.

 

-15-
 

 

ODYSIGHT.AI INC.

 

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 5 – EQUITY (continued):

 

Restricted stock unit (“RSU”) activity

 

Each RSU vests based on continued service to the Company, generally over three years. The grant date fair value of the award is recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s common stock.

 

The following table summarizes RSU activity for the nine months ended September 30, 2026 and September 30, 2025:

 

   For the Nine months ended 
   September 30, 
   2026   2025 
   Number of  

Weighted

Average

Grant Date

Fair Value

   Number of  

Weighted

Average

Grant Date

Fair Value

 
   RSUs   per Share ($)   RSUs   per Share ($) 
Outstanding at beginning of period   4,167    3.00    15,419    3.56 
Granted   -    -    -    - 
Forfeited   -    -    -    - 
Vested   (4,167)   3.00    (9,168)   3.94 
Unvested and Outstanding at end of period   -    -    6,251    3.0 

 

The following table sets forth the total stock-based payment expenses resulting from options and RSUs granted, included in the statements of operations and comprehensive loss:

 

   2026   2025   2026   2025 
  

Nine months ended

September 30,

  

Three months ended

September 30,

 
   2026   2025   2026   2025 
   Unaudited 
   USD in thousands 
                 
Cost of revenues   -    (3)   -    - 
Research and development   435    807    168    341 
Sales and marketing expenses   341    297    120    95 
General and administrative   1,026    1,464    176    478 
Total expenses   1,802    2,565    464    914 

 

-16-
 

 

ODYSIGHT.AI INC.

 

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 6 – REVENUES:

 

  a. Disaggregation of revenue:

 

  (1) During the second quarter of 2022, the Company completed the development of a customer-specific project for a Fortune 500 medical company customer (the “Client”) and moved from the project development phase to its production phase. Through the first quarter of 2025, the Company recognized development services revenues and costs that had been previously deferred based on the expected manufacturing term of the product, which the Company estimated originally at seven years. During the first quarter of 2025, due to the fact that the Company had not received a purchase order from the Client and did not expect to receive such order, the Company decided to fully derecognize the contract fulfillment asset and contract liability associated with the Client, in the amount of $957 thousand and $1,690 thousand, respectively.
     
  (2) During the nine months ended September 30, 2026, the Company recognized revenues from customization and development services in which the performance obligation is satisfied over time in the amount of $915 thousand.

 

  b. Unbilled receivables, Contract fulfillment assets, Contract liabilities and Advances from customers:

 

Unbilled receivables represent revenue recognized for goods or services delivered to a customer, but not yet invoiced.

 

The change in unbilled receivables:

 

 

   September 30,   December 31, 
   2026   2025 
   USD in thousands 
Balance at beginning of period   615    185 
Contract revenues recognized during the period   142    430 
Balance at end of period   757    615 

 

The change in contract fulfillment assets:

 

   September 30,   December 31, 
   2026   2025 
   USD in thousands 
Balance at beginning of period   -    1,017 
Contract costs recognized during the period   -    (1,017)
Balance at end of period   -    - 

 

Contract liabilities include deferred service and advance payments.

 

The change in contract liabilities and in advances from customers:

 

   September 30,   December 31, 
   2026   2025 
   USD in thousands 
Balance at beginning of period   165    2,075 
Advances from customers during the period   40    178 
Revenue recognized during the period   (110)   (2,088)(*)
Balance at end of period   95    165 

 

(*)Includes the full derecognition of contract liability associated with the Client, in the amount of $1,690 thousand, as described in Note 6(a)(1).

 

Remaining Performance Obligations

 

Remaining Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that are expected to be invoiced and recognized as revenue in future periods. As of September 30, 2026, the total RPO amounted to approximately $16.0 million.

 

-17-
 

 

ODYSIGHT.AI INC.

 

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 7 – INVENTORY:

 

Composed as follows:

 

   September 30,   December 31, 
   2026   2025 
   USD in thousands 
Raw materials and supplies   193    50 
Finished goods   279    - 
Total inventory   472    50 

 

During the nine months ended September 30, 2026, no impairment occurred.

 

During the nine months ended September 30, 2025, the Company recognized an inventory impairment related to a medical client in the amount of $203 thousand. See Note 6(a)(1).

 

NOTE 8 – LOSS PER SHARE

 

Basic loss per share is computed by dividing net loss attributable to common stockholders of the Company by the weighted average number of common shares as described below.

 

Basic net loss per share is computed based on the weighted average number of shares outstanding during each period. Diluted net loss per share is computed based on the weighted average number of shares outstanding during each period, plus the dilutive potential of the common stock considered outstanding during the period, in accordance with ASC 260-10, “Earnings per Share.”

 

All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the period, since all such securities have an anti-dilutive effect.

 

The following table represents potential common shares outstanding that were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive:

 

   September 30,   December 31, 
   2026   2025 
Options   3,630,520    3,340,514 
Restricted stock unit   -    4,167 
Warrants   -    5,763,273 
    3,630,520    9,107,954 

 

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

In April 2023, the Company received approval from the Israel Innovation Authority (the “IIA”) to support and enhance the Company’s production line and capabilities in the next 24 months until April 2025. Pursuant to the agreement with the IIA relating to the program, the Company is required to pay royalties of 3% to the IIA up to the amount of IIA funding received and the accrued interest. Repayment of the grant is contingent upon the Company successfully completing its enhancement plans and generating sales from the enhancements performed.

 

Total IIA royalty-bearing grants approved for the Company amounted to approximately $80,000.

 

The Company does not currently expect to repay these grants as its enhancement plans are not completed, are aborted or have generated no sales.

 

-18-
 

 

ODYSIGHT.AI INC.

 

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 10 – SEGMENT REPORTING

 

Segment information is prepared on the same basis that the chief executive officer, who is the Company’s chief operating decision maker, manages the business, makes business decisions and assesses performance. The Company has one reportable segment specializing in vision-based platform solutions as described in Note 1.

 

The chief executive officer assesses performance for this segment and decides how to allocate resources. The measure of segment assets is reported on the balance sheet as total assets. The chief executive officer performs the assessment of segment performance by using the reported measure of segment profit or loss to monitor budget versus actual results.

 

The table below summarizes the significant expense categories regularly reviewed by the chief operating decision maker for the nine months and three months ended September 30, 2026 and 2025:

 

   2026   2025   2026   2025 
   Nine months ended September 30,   Three months ended September 30, 
   2026   2025   2026   2025 
   Unaudited 
   USD in thousands 
     
Revenues   926    2,576    424    149 
                     
Cost of Revenues (*)   555    1,875    233    126 
                     
Research and Development expenses (*)   6,476    6,454    1,993    2,114 
                     
Sales and marketing (*)   2,410    1,305    749    486 
                     
General and Administrative expenses (*)   3,719    3,994    1,262    1,186 
                     
Other segment items:                    
Stock-based payments   1,802    2,565    464    914 
Depreciation   82    88    26    30 
Loss from sales of property and equipment   97    -    43    - 
Finance income, net   496    949    132    291 
                     
Net loss   (13,719)   (12,756)   (4,214)   (4,416)

 

(*)   Excluding share-based payments, depreciation expense, loss from sales of property and equipment and finance income, net.

 

NOTE 11 – SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date the financial statements were issued and identified none requiring disclosure or adjustment.

 

-19-
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our interim condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2025. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Special Note Regarding Forward-Looking Statements.” You should review the “Risk Factors” in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

Overview

 

We were incorporated under the laws of the State of Nevada on March 22, 2013, under the name Intellisense Solutions Inc.

 

On December 30, 2019, we acquired all of the issued and outstanding share capital of ScoutCam Ltd. and, on December 31, 2019, we changed our name to ScoutCam Inc. Following this acquisition, we integrated and fully adopted the acquired miniaturized imaging business as our primary business activity. On June 5, 2023, we changed our name to Odysight.ai Inc. On February 11, 2025, our common stock began trading on the Nasdaq Capital Market under the symbol “ODYS,” and on April 9, 2026, our common stock began trading on the Tel Aviv Stock Exchange under the same symbol.

 

We are a pioneer in the development, production and marketing of an innovative visual monitoring AI solution that deploys small visual sensors to monitor critical safety components in hard-to-reach locations and harsh environments, across various Predictive Maintenance, or PdM, and Condition Based Monitoring, or CBM, use cases applied both for the civil and defense sectors. We aim to be the industry benchmark for real-time, visual-based machine and infrastructure health monitoring and predictive maintenance analysis through AI and machine learning (ML) data analytics.

 

Our solution streams visual information to our processing unit, an in-platform, high-performance AI and ML computer, allowing maintenance and operations teams, on the ground and during operations, visibility into areas that are inaccessible under normal operating conditions or where conditions are not suitable for continuous monitoring. The data, continuously collected and analyzed by our solution on our secured cloud, provides customers with real-time failure / anomaly detection, events and data recordings, interfacing with platform mission systems and providing real-time alerts and streaming video or images, all while training our algorithms for ongoing improved accuracy and prediction capabilities. Our customers use the prediction capabilities of our solution to efficiently plan maintenance work on monitored components, benefiting from increased safety, a reduction in downtime, a more efficient data-driven operation, increased mission readiness and lower maintenance costs for their monitored platforms.

 

Our solution enhances safety and minimizes downtime by enabling real-time visual analysis of any failure occurrences and leveraging advanced big data analytics to offer predictive insights throughout the entire system lifecycle. This includes efficient spare parts management and intelligent performance predictions, ensuring optimal system reliability and efficiency.

 

Our solutions are already deployed in the aviation, industrial and automotive sectors. While historically, our revenue stream has been derived mainly from the medical sector, today our customers include the Israeli Air Force, the Israeli Ministry of Defense, Honeywell Aerospace, a global defense contractor, the National Aeronautics and Space Administration (NASA) and Israel Railways Ltd., as well as a leading European provider of elevator monitoring solutions. We have also entered into a Cooperative Research and Development Agreement (CRADA) with the Naval Air Warfare Center Aircraft Division Lakehurst (NAWCAD).

 

-20-
 

 

Public Offering, Nasdaq Listing and TASE Listing

 

In February 2025, we closed a public offering, including the exercise of an over-allotment option granted to the underwriters in the public offering. The public offering price and the over-allotment option exercise price were $6.50 per share. In the aggregate, we sold a total of 3,653,124 shares of common stock, generating gross proceeds of approximately $23.7 million, prior to the deduction of underwriting discounts, commissions and estimated offering expenses. After deducting issuance costs, we received net proceeds of approximately $20.9 million. Also in February 2025, our common stock began trading on the Nasdaq Capital Market under the symbol “ODYS”.

 

On April 9, 2026, our common stock began trading on the TASE under the same symbol “ODYS” following our application to voluntarily list our shares of common stock on the TASE.

 

On August 21, 2026, we completed an underwritten public offering of 3,437,500 shares of our common stock at a price of $3.20 per share. We also granted the underwriters a 30-day over-allotment option to purchase up to an additional 515,625 shares at a purchase price of $3.20 per share. The option expired without being exercised. The gross proceeds of the offering were approximately $11.0 million, prior to the deduction of underwriting discounts, commissions and offering expenses. After deducting issuance costs, we received net proceeds of approximately $9.8 million.

 

Impact of the Ongoing War in the Middle East on Our Business

 

In October 2023, the Hamas terrorist organization launched a series of terror attacks on civilian and military targets adjacent to the Gaza Strip in southern Israel. Israel subsequently declared war and commenced a military campaign against Hamas. While the parties reached a framework in October 2025 that contemplates a potential permanent end to the war with Hamas, there can be no assurance that any ceasefire will be sustained or will result in a lasting resolution. Furthermore, Israel has experienced hostilities on other fronts, including with Hezbollah along Israel’s northern border, attacks and threats from the Houthis in Yemen and several significant direct confrontations with Iran. The security situation escalated significantly on February 28, 2026, when the United States and Israel attacked Iran, which responded with missile and drone attacks on Israel, U.S. forces and other targets in the region, causing civilian casualties and property damage in Israel. In March 2026, Hezbollah joined the conflict, leading to Israeli strikes and a ground incursion in Lebanon.

 

Ceasefire arrangements reached between April and June 2026, including a June 2026 U.S.-Iran memorandum of understanding, have been repeatedly violated, and the memorandum collapsed in July 2026 amid renewed hostilities in the Strait of Hormuz, which remains largely closed to commercial shipping. The situation remains volatile and future developments are difficult to predict. In November 2026, U.S. President Donald Trump reportedly announced that U.S. military aid to Israel, currently approximately $3.8 billion annually, would end after 2026. The timing and terms remain unclear, but any reduction or termination of such aid could adversely affect the Israeli Ministry of Defense budget and procurement on which our Israeli defense business depends. To date, the closure of the Strait of Hormuz has not had a material impact on our supply chain, logistics or component costs. The conclusion of wars or other conflicts may result in changes to regional alliances, shifts in security postures, and the imposition of new sanctions or trade restrictions, any of which could have an adverse impact on our operations. Additionally, such periods may be characterized by heightened uncertainty, including the possibility of contentious political debate and protests, economic instability or changes in government policies that could adversely affect the Israeli economy and, in turn, our business, financial condition and results of operations.

 

Although these conflicts have not had a material adverse effect on our business to date, we have experienced disruptions to work routines, periodic travel limitations and occasional rocket fire requiring employees at our Omer and Ramat Gan offices to take temporary shelter. Our offices were closed on certain days during the recent rounds of conflict with Iran and Hezbollah pursuant to instructions from Israel’s Home Front Command. To mitigate these effects, we have adopted work-from-home measures, increased employee overtime and utilized third-party outsourcing where necessary. Furthermore, many of our employees and executives are obligated to perform military reserve duty. Since October 2023, several of our executives, including our CEO, have been periodically called up to active duty. Our operations could be disrupted by future call-ups and by the absence of a significant number of our employees or key management members.

 

The ongoing conflict has influenced our commercial environment in the following ways:

 

  ● Customer Prioritization: During more intense periods of the conflict, including during the recent rounds of hostilities with Iran, some Israeli clients have prioritized other matters, which has caused occasional delays in finalizing purchase orders and deliveries of existing projects. These delays have had a temporary impact on our business.
     
  ● Defense Technology Interest: Conversely, due to intensive flight hours flown by the Israeli Air Force and an enhanced Ministry of Defense budget, we have seen growing interest in our technology from Israeli government agencies and R&D programs. This may lead to a more rapid assimilation of our technology into relevant platforms than previously anticipated. However, there can be no assurance that this interest will continue or result in orders, particularly if the Israeli Ministry of Defense budget is reduced or its approval is delayed, including as a result of any reduction in U.S. military aid to Israel or the current political uncertainty in Israel. See Part II, Item 1A, “Risk Factors.”
     
  ● International Sentiment: The war has increased negative sentiments regarding Israel and Israeli companies internationally, including efforts to boycott Israeli goods and services and specific efforts targeting Israeli defense firms. While we have faced challenges, such as initial bans from industry conferences that were later overturned, these efforts have not impacted our participation in such events to date.
     
  ● Insurance Coverage: Our insurance policies do not cover losses that may occur as a result of war and terrorism. While the Israeli government currently covers the reinstatement value of direct damages caused by such acts, there is no assurance this coverage will be maintained or will sufficiently cover our potential damages. Any significant damage to our facilities or disruption of trade between Israel and its trading partners could have a material adverse effect on our business.

 

Comparison of the nine months ended September 30, 2026 and 2025

 

The following table summarizes our results of operations for the nine-month periods ended September 30, 2026 and 2025, together with the changes in those items in dollars in thousands and as a percentage:

 

   Nine months ended September 30,     
   2026   2025   % Change 
Revenues   926    2,576    (64)%
Cost of Revenues   555    1,882    (71)%
Gross Profit   371    694    (47)%
Research and development expenses   6,979    7,322    (5)%
Sales and marketing expense   2,752    1,604    72%
General and administrative expenses   4,855    5,473    (11)%
Operating Loss   (14,215)   (13,705)   4%

 

-21-
 

 

Revenues

 

As a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from a limited number of customers.

 

For the nine months ended September 30, 2026, we generated revenues of $926 thousand, compared to $2,576 thousand for the nine months ended September 30, 2025. The decrease in revenues was mainly attributable to $1,862 thousand of revenues recognized in the first quarter of 2025 from a Fortune 500 medical company customer, of which $1,690 thousand resulted from the full derecognition of a contract liability, a non-recurring item.

 

Revenues for the first nine months of $926 thousand are primarily attributable to the aerospace domain and are up 29% compared to $714 thousand for the nine months ended September 30, 2025 in the same domain.

 

Cost of Revenues

 

Cost of revenues was $555 thousand for the nine months ended September 30, 2026, compared to $1,882 thousand for the nine months ended September 30, 2025. In the first nine months ended September 30, 2025 we had additional costs of approximately $1,412 thousand related to the medical domain.

 

Cost of revenues for the first nine months of $555 thousand was primarily attributable to the aerospace domain, compared to $470 thousand for the nine months ended September 30, 2025 in the same domain.

 

Gross Profit

 

Gross profit was $371 thousand for the nine months ended September 30, 2026, compared to gross profit of $694 thousand for the nine months ended September 30, 2025. In the first nine months ended September 30, 2025 we had additional profit of approximately $450 thousand related to the medical domain.

 

Gross Profit for the first nine months of $371 thousand was primarily attributable to the aerospace domain, compared to $244 thousand for the nine months ended September 30, 2025 in the same domain.

 

Research and Development Expenses

 

Research and development efforts are focused on developing additional functionality for our new and existing products, as well as monitoring new product development. These expenses primarily consist of employee-related expenses, including salaries, benefits and stock-based compensation expense for personnel engaged in research and development functions, consulting and professional fees related to research and development activities, prototype materials, facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation and other supplies. We expense research and development costs as incurred.

 

Research and development expenses for the nine months ended September 30, 2026 were $6,979 thousand, compared to $7,322 thousand for the nine months ended September 30, 2025.

 

The decrease in research and development expenses for the nine months ended September 30, 2026 was primarily attributable to the rebuilding of our research and development teams, as well as workforce efficiency measures taken with subcontractors, the adoption of AI tools and a decrease in stock-based compensation. This decrease was partly offset by an increase in expenses due to foreign exchange rate fluctuations resulting from the appreciation of the Israeli Shekel.

 

-22-
 

 

Sales and Marketing Expenses

 

Sales and marketing expenses primarily consist of payroll expenses, consulting services, promotional materials, exhibitions, demonstration equipment, travel and certain allocated facility infrastructure costs.

 

Sales and marketing expenses for the nine months ended September 30, 2026 were $2,752 thousand, compared to $1,604 thousand for the nine months ended September 30, 2025.

 

The increase in sales and marketing expenses was primarily driven by our enhanced global selling and marketing activities, including efforts to penetrate new territories and market verticals and enhance product visibility. This led to higher expenses associated with the recruitment of new personnel and marketing consultants and the reclassification of two employees to the Sales and Marketing department.

 

General and Administrative Expenses

 

General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, public relations, accounting, auditing, tax services and insurance costs.

 

General and administrative expenses for the nine months ended September 30, 2026 were $4,855 thousand, compared to $5,473 thousand for the nine months ended September 30, 2025.

 

The decrease in general and administrative expenses was primarily due to a decrease in expenses related to our fundraising and uplisting to Nasdaq, which occurred during the three months ended March 31, 2025, and a decrease in stock-based compensation.

 

Operating Loss

 

We incurred an operating loss of $14,215 thousand for the nine months ended September 30, 2026, compared to an operating loss of $13,705 thousand for the nine months ended September 30, 2025.

 

The increase in operating loss was due to a decrease in gross profit and an increase in sales and marketing expenses, each as described above, partially offset by a decrease in research and development expenses and in general and administrative expenses.

 

Cash Flows

 

Our primary uses of cash from operating activities have been for payroll expenses, research and development costs, manufacturing costs, marketing and promotional expenses, professional services costs and costs related to our facilities.

 

The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars in thousands):

 

   Nine months ended September 30, 
   2026   2025 
Cash used in Operating Activities   (13,014)   (9,821)
Cash provided by (used in) Investing Activities   (352)   269 
Cash provided by Financing Activities   10,076    21,057 

 

Operating Activities

 

During the nine months ended September 30, 2026, cash used in operating activities was $13.0 million, consisting of net loss of $13.7 million and an unfavorable net change in operating assets and liabilities of $1.2 million, partially offset by a non-cash benefit of $1.9 million. Our non-cash benefit consisted primarily of non-cash charges for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash outflows from changes in accounts receivable, an increase in inventory, an increase in current and non-current other assets and a decrease in operating lease liability, partially offset by inflows from a decrease in right-of-use asset.

 

During the nine months ended September 30, 2025, cash used in operating activities was $9.8 million, consisting of net loss of $12.8 million, partially offset by a favorable net change in operating assets and liabilities of $0.3 million and a non-cash benefit of $2.6 million. Our non-cash benefit consisted primarily of non-cash charges for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in accounts receivable and a decrease in contract fulfillment assets, partially offset by outflows from changes in current and non-current contract liabilities and advances from customers.

 

-23-
 

 

Investing Activities

 

During the nine months ended September 30, 2026, cash used in investing activities was $0.4 million, attributable mainly to an investment in short-term deposits.

 

During the nine months ended September 30, 2025, net cash provided by investing activities was $0.3 million, consisting mainly of a withdrawal of short-term deposits.

 

Financing Activities

 

During the nine months ended September 30, 2026, cash provided by financing activities was $10.1 million, consisting of cash proceeds from issuance of shares, net of issuance costs, and proceeds from options exercise.

 

During the nine months ended September 30, 2025, cash provided by financing activities was $21.1 million, consisting of cash proceeds from issuance of shares, net of issuance costs, and proceeds from options exercise.

 

Comparison of the three months ended September 30, 2026 and 2025

 

The following table summarizes our results of operations for the three-month periods ended September 30, 2026 and 2025, together with the changes in those items in dollars in thousands and as a percentage:

 

   Three months ended September 30,     
   2026   2025   % Change 
Revenues   424    149    185%
Cost of Revenues   233    126    85%
Gross Profit   191    23    730%
Research and development expenses   2,182    2,479    (12)%
Sales and marketing expense   869    580    50%
General and administrative expenses   1,486    1,671    (11)%
Operating Loss   (4,346)   (4,707)   (8)%

 

Revenues

 

As a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from a limited number of customers.

 

For the three months ended September 30, 2026, we generated revenues of $424 thousand, compared to $149 thousand for the three months ended September 30, 2025.

 

The increase in revenue was primarily driven by the completion of ongoing projects, coupled with the commencement of new projects and continued progress on existing projects.

 

Cost of Revenues

 

Cost of revenues for the three months ended September 30, 2026 was $233 thousand, compared to cost of revenues of $126 thousand for the three months ended September 30, 2025.

 

The increase in cost of revenues is consistent with the increase in revenues and primarily attributable to the same factors.

 

Gross Profit

 

Gross profit for the three months ended September 30, 2026 was $191 thousand, compared to gross profit of $23 thousand for the three months ended September 30, 2025.

 

The increase in gross profit was due to the increase in revenues, partially offset by the increase in cost of revenues, as described above.

 

-24-
 

 

Research and Development Expenses

 

Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits and stock-based compensation expense for personnel engaged in research and development functions, consulting and professional fees related to research and development activities, prototype materials, facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation and other supplies. We expense research and development costs as incurred.

 

Research and development expenses for the three months ended September 30, 2026 were $2,182 thousand, compared to $2,479 thousand for the three months ended September 30, 2025.

 

The decrease in research and development expenses for the three months ended September 30, 2026 was primarily attributable to the rebuilding of our research and development teams, as well as efficiency steps taken with subcontractors, the adoption of AI tools and a decrease in stock-based compensation.

 

Sales and Marketing Expenses

 

Sales and marketing expenses primarily consist of payroll and related expenses, consulting services, promotional materials, exhibitions, demonstration equipment, travel and certain allocated facility infrastructure costs.

 

Sales and marketing expenses for the three months ended September 30, 2026 were $869 thousand, compared to $580 thousand for the three months ended September 30, 2025.

 

The increase in sales and marketing expenses was primarily driven by our enhanced global selling and marketing activities, including efforts to penetrate new territories and market verticals and enhance product visibility. This led to higher expenses associated with the recruitment of new personnel and marketing consultants.

 

General and Administrative Expenses

 

General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, public relations, accounting, auditing, tax services and insurance costs.

 

General and administrative expenses for the three months ended September 30, 2026 were $1,486 thousand, compared to $1,671 thousand for the three months ended September 30, 2025.

 

The decrease in general and administrative expenses was primarily due to a decrease in stock-based compensation, partially offset by an increase in expenses due to foreign exchange rate fluctuations resulting from the appreciation of the Israeli Shekel.

 

Operating Loss

 

We incurred an operating loss of $4,346 thousand for the three months ended September 30, 2026, compared to an operating loss of $4,707 thousand for the three months ended September 30, 2025.

 

The decrease in operating loss was due to an increase in gross profit, a decrease in research and development expenses and a decrease in general and administrative expenses, partially offset by an increase in sales and marketing expenses, each as described above.

 

-25-
 

 

Cash Flows

 

Our primary uses of cash from operating activities have been for payroll expenses, research and development costs, manufacturing costs, marketing and promotional expenses, professional services costs and costs related to our facilities.

 

The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars in thousands):

 

   Three months ended September 30, 
   2026   2025 
Cash used in Operating Activities   (4,301)   (3,418)
Cash used in Investing Activities   (9)   (11)
Cash provided by Financing Activities   9,943    1 

 

Operating Activities

 

During the three months ended September 30, 2026, cash used in operating activities was $4.3 million, consisting of net loss of $4.2 million and an unfavorable net change in operating assets and liabilities of $0.6 million, partially offset by a non-cash benefit of $0.5 million. Our non-cash benefit consisted primarily of non-cash charges of $0.5 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash outflows from decrease in operating lease liability, increase in current and non-current assets, increase in inventory, and decrease in current and non-current contract liabilities and advances from customers, partially offset by cash inflows from decrease in accounts receivable and decrease in right-of-use assets.

 

During the three months ended September 30, 2025, cash used in operating activities was $3.4 million, consisting of net loss of $4.4 million and a non-cash benefit of $1.0 million. Our non-cash benefit consisted primarily of non-cash charges of $0.9 million for stock-based compensation.

 

Investing Activities

 

For the three months ended September 30, 2026, net cash used in investing activities was $9 thousand, attributable to purchases of property and equipment, partially offset by proceeds from the sale of property and equipment.

 

For the three months ended September 30, 2025, net cash used in investing activities was $11 thousand, attributable to a purchase of property and equipment.

 

Financing Activities

 

For the three months ended September 30, 2026, net cash provided by financing activities was $9.9 million, attributable to proceeds from issuance of shares, net of issuance costs.

 

For the three months ended September 30, 2025, net cash provided by financing activities was $1 thousand, consisting of proceeds from options exercise, partially offset by issuance expenses.

 

Backlog

 

Backlog represents booked orders based on purchase orders or hard commitments but not yet recognized as revenue. Orders included in backlog may be cancelled or rescheduled by customers. A variety of conditions, both specific to the individual customer and generally affecting the customer’s industry, may cause customers to cancel, reduce or delay orders that were previously made or anticipated. We cannot assure the timely replacement of cancelled, delayed or reduced orders. Backlog is presented for supplemental informational purposes only and is not intended to be a substitute for any GAAP financial measures, including revenue or net income (loss), and, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. In addition, backlog should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Therefore, backlog should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP.

 

Our backlog as of September 30, 2026 was approximately $16.0 million compared to approximately $13.8 million as of December 31, 2025.

 

Liquidity and Capital Resources

 

Overview

 

As of September 30, 2026, we had cash and cash equivalents and restricted deposit of approximately $23.2 million compared to cash and cash equivalents and restricted cash of approximately $26.0 million as of December 31, 2025. In addition, as of September 30, 2026, we had an accumulated deficit of $76.7 million compared to $63.0 million as of December 31, 2025.

 

Our primary sources of liquidity to date have been from fundraising, revenues from customers, and warrant and option exercises. On August 21, 2026, we completed an underwritten public offering of 3,437,500 shares of our common stock at a price of $3.20 per share. We also granted the underwriters a 30-day over-allotment option to purchase up to an additional 515,625 shares at a purchase price of $3.20 per share. The option expired without being exercised. The gross proceeds of the offering were approximately $11.0 million, prior to the deduction of underwriting discounts, commissions and offering expenses. After deducting issuance costs, we received net proceeds of approximately $9.8 million. Our Sales Agreement, dated June 5, 2026, with Roth Capital Partners, LLC, as sales agent, was terminated effective August 21, 2026.

 

Additional Cash Requirements

 

We plan to continue to invest in long-term growth, and therefore our expenses may continue to grow. We currently believe that our existing cash and cash equivalents will allow us to fund our operating plan through at least the next 12 months from the date of this Quarterly Report on Form 10-Q. Our expenses may increase in connection with our ongoing activities, particularly as we continue our commercialization efforts, research and development and the scale-up of our solutions. We expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we expect that we will need to raise additional capital before we become profitable from sales of our solutions and may do so to expand our business, pursue strategic investments, take advantage of financing opportunities or for other reasons. We may raise these funds through equity financing, debt financing or other sources, which may result in further dilution in the equity ownership of our common stock. There is no assurance that we will be able to maintain operations at a level sufficient for investors to obtain a return on their investment in our common stock, or that we will be able to raise sufficient capital required to implement our business plan on acceptable terms, if at all. Even if we are successful in raising sufficient capital to implement our business plan, we will, most likely, continue to be unprofitable for the foreseeable future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

 

-26-
 

 

Contractual Obligations and Commitments

 

Operating lease payments represent our commitment for future payments under leases for our offices in Israel and for vehicle leasing. The total future payments for our operating lease obligations as of September 30, 2026 were approximately $711 thousand. For additional details regarding our leases, see Note 3 to our interim condensed consolidated financial statements for the nine months ended September 30, 2026.

 

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

As a smaller reporting company, we are not required to provide the information requested by this Item.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

 

No change in our internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f), occurred during the fiscal quarter ended September 30, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

-27-
 

 

PART II- OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.

 

ITEM 1A. RISK FACTORS

 

Except as set forth below, there have been no material changes from the information set forth in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 19, 2026.

 

Political and economic conditions in Israel could materially and adversely affect our business, financial condition and results of operations.

 

The following supplements the risk factor captioned “Our headquarters and other significant operations are located in Israel and therefore our business, financial condition and results of operation may be adversely affected by political, economic and military instability in Israel” in our Annual Report on Form 10-K. Israel is currently experiencing significant political uncertainty. The general election held in October 2026 did not produce a clear parliamentary majority for any political bloc, and the formation of a new government remains uncertain. If a government cannot be formed, Israel may hold further elections, and the outgoing government would continue to serve in a caretaker capacity in the meantime, with limited ability to adopt new policies or approve a state budget. Israel has experienced similar periods of political deadlock in recent years, including repeated elections between 2019 and 2022 and extended periods without a permanent government or an approved budget. A prolonged period of political deadlock, caretaker government or repeated elections could delay or disrupt government decisions, procurement decisions, defense budget approvals and regulatory or contracting processes on which our Israeli defense business depends. It could also adversely affect the Israeli economy, Israel’s sovereign credit ratings and Israeli capital markets.

 

The security situation in Israel and the Middle East, and potential changes in U.S. military aid to Israel, could materially and adversely affect our business, financial condition and results of operations.

 

Since the filing of our Annual Report on Form 10-K, ceasefire arrangements involving Israel, the United States and Iran have been repeatedly violated, and the June 2026 U.S.-Iran memorandum of understanding collapsed in July 2026 amid renewed hostilities in the Strait of Hormuz, which remains largely closed to commercial shipping. Continued or escalated hostilities could disrupt our operations, including through office closures, the call-up of our employees and executives for military reserve duty and delays in customer orders and deliveries, and could disrupt the shipment of components and products or increase our costs. In addition, in November 2026, U.S. President Donald Trump reportedly announced that U.S. military aid to Israel would end after 2026. A portion of our business is dependent on the Israeli Ministry of Defense and the Israeli Air Force, and any reduction or termination of U.S. military aid could potentially reduce or delay Israeli defense procurement, which could adversely affect future potential deals.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

During the three months ended September 30, 2026, we did not have any sales of unregistered securities.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

Director Rule 10b5-1 Trading Arrangement

 

Other than as described below, during the quarter ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).

 

On August 31, 2026 Inbal Kreiss, a member of the Company’s Board of Directors, adopted a trading arrangement for the sale of shares of the Company’s common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The arrangement provides for the sale of common stock issuable upon the exercise of certain stock options held by Ms. Kreiss. The trading arrangement expires on the earlier of November 30, 2027 and the completion of all sales under the arrangement. Pursuant to the arrangement, the aggregate number of shares for which such options are to be exercised, and the aggregate number of shares of common stock to be sold upon exercise of those options, is not to exceed 61,025.

  

Amended and Restated Bylaws

 

On November 12, 2026, the Company’s Board of Directors approved and adopted Amended and Restated Bylaws of the Company (as so amended and restated, the “Bylaws”), which became effective immediately upon such approval. The Bylaws were amended principally to conform the Company’s bylaws to applicable provisions of Nevada law and to make certain related updates. The Bylaws were amended to, among other things:

 

  ● eliminate the ability of stockholders to act by written consent, such that any action required or permitted to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders (previously, unless otherwise prohibited under exchange rules, stockholders holding a majority of the shares entitled to vote could act by written consent without a meeting);
  ● provide that any director, or the entire Board of Directors, may be removed from office by the affirmative vote of stockholders representing not less than two-thirds of the voting power of the issued and outstanding stock entitled to vote (or such greater percentage as may be set forth in the Articles of Incorporation), in accordance with Section 78.335 of the Nevada Revised Statutes (the “NRS”) (previously the bylaws provided that directors could be removed only for cause and only by the affirmative vote of the holders of at least 70% of the voting power of the outstanding shares entitled to vote in the election of directors);
  ● require the Board of Directors to fix a new record date if a stockholder meeting is adjourned to a date more than 60 days after the date set for the original meeting, as required by NRS 78.350, with notice of the adjourned meeting to be given to stockholders of record as of the new record date (previously, the bylaws contemplated new notice if a meeting was adjourned for more than 30 days or a new record date was fixed);
  ● delete the requirement that the Company prepare and make available for examination, at least 10 days before each stockholder meeting, a list of the stockholders entitled to vote at the meeting; and
  ● provide that stockholders have such rights to inspect and copy the Company’s books and records as are provided by, and subject to the conditions and limitations of, the NRS, including NRS 78.105 and NRS 78.257, as applicable (previously, any stockholder of record could inspect the stock ledger, stockholder list and other books and records for any proper purpose upon written demand under oath).

 

The Bylaws also include certain technical, conforming and clarifying changes.

 

The foregoing description of the Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Bylaws, a copy of which is filed as Exhibit 3.2.1 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.

 

-28-
 

 

ITEM 6. EXHIBITS

 

  (a) The following documents are filed as exhibits to this Quarterly Report on Form 10-Q or incorporated by reference herein.

 

Exhibit

Number

  Description
     
3.1.1   Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1.1 to our Form S-1 filed with the SEC on July 17, 2023)
     
3.2.1*   Amended and Restated Bylaws adopted November 12, 2026
     
31.1*   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
     
31.2*   Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
     
32.1**   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2**   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
     
*   Filed herewith.
     
**   Furnished herewith.

 

-29-
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 16, 2026 ODYSIGHT.AI INC
     
  By: /s/ Yehu Ofer
  Name: Yehu Ofer
  Title: Chief Executive Officer
    Odysight.ai Inc
     
  By: /s/ Einav Brenner
  Name: Einav Brenner
  Title: Chief Financial Officer
    Odysight.ai Inc

 

-30-

 

Keep reading